Drug Target Review – Issue 3 2021
Posted: 22 September 2021 | Drug Target Review | No comments yet
In this issue, find articles exploring why CRISPR is useful for high-throughput drug discovery, how targeting telomerase may lead to universal cancer vaccines and a new study to identify therapeutics that can be repurposed against COVID-19. Also included are features on neuroscience, organoids and antibodies.
Included in this issue:
- VACCINE DEVELOPMENT
An integrated vaccination approach to neurodegeneration
Dr Andrea Pfeifer, AC Immune - NEUROSCIENCE
Using brain models of patient-specific Alzheimer’s insights
Victoria Rees, Drug Target Review - SYNTHETIC BIOLOGY
The diversity of synthetic biology applications
Dr Jim Collins, MIT and Wyss Institute at Harvard University - ORGANOIDS
High-throughput 3D cell migration assays in organ-on-a-chip technologies
Dr Désirée Goubert, Thomas Olivier, Luuk de Haan and Dr Lenie van den Broek, MIMETAS - ANTIBODIES
An IgM antibody platform to tackle SARS‑CoV-2 and its variants
Dr Steve Carroll, IGM Biosciences - TARGETS
Targeting disease pathways to treat ulcerative colitis – beyond corticosteroid use
Dr Chetan Karyekar, Janssen - ASSAYS
Improving drug discovery with advanced targeted proteomic monitoring workflows
Professor Forest White, MIT
Dr Lauren Stopfer, BioNTech
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Antibodies, Assays, CRISPR, Drug Discovery, Genome editing, Molecular Targets, Nanomedicine, Neurosciences, Screening, Vaccine
